Drug Interaction Report
1 drug interaction and 14 additional warnings found for the following 2 drugs:
- Gloperba (colchicine)
- tucatinib
Drug interactions
Major drug interactions
Major:colchicine tucatinib
Applies to: Gloperba (colchicine), tucatinib
Tucatinib may increase the blood levels of colchicine to dangerous levels, increasing the risk of serious side effects that can affect your muscles, blood cells, nervous system, and multiple organs including the liver and kidneys.
Before taking colchicine let your doctor know if you are currently using tucatinib or have used it within the last 14 days. Depending on your condition and the brand of colchicine you take, your doctor may interrupt treatment with colchicine, lower your dose of colchicine, or may decrease the frequency of colchicine doses.
Let your doctor know if you experience abdominal pain, nausea, vomiting, diarrhea, fever, muscle pain, weakness, fatigue, and/or numbness or tingling in your hands and feet, as these may be early symptoms of colchicine toxicity.
You may not be able to take these medications together if you have liver or kidney disease.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:Food/Lifestyle colchicine
Applies to: Gloperba (colchicine)
Drinking large amounts of grapefruit juice can increase your blood levels of colchicine to dangerous levels.
You should avoid the consumption of grapefruit or grapefruit juice during treatment with colchicine.
Let your doctor know if you experience abdominal pain, nausea, vomiting, diarrhea, fever, muscle pain, weakness, fatigue, and/or numbness or tingling in your hands and feet, as these may be early symptoms of colchicine toxicity.
Disease interactions
13 potential interactionsApplies to: 9 conditions, including Hypokalemia, Hyperkalemia, Liver Disease, Hyponatremia, and Cardiovascular Conditions and Disorders.
Bone Marrow Depression/Low Blood Counts
Major:Gloperba
The colchicine in Gloperba has a major potential interaction with Bone Marrow Depression/Low Blood Counts.
The use of colchicine should be used with caution in patients with bone marrow suppression. Patients on long term therapy may require periodic blood counts.
Cardiovascular Conditions and Disorders
Major:Gloperba
The colchicine in Gloperba has a major potential interaction with Cardiovascular Conditions and Disorders.
The use of colchicine should be used with caution in patients with cardiac dysfunction. The possibility of cumulative effects of colchicine is increased in these patients.
Disseminated Intravascular Coagulation
Major:Gloperba
The colchicine in Gloperba has a major potential interaction with Disseminated Intravascular Coagulation.
Colchicine should be used with caution in patients with disseminated intravascular coagulation. Debilitated patients have an increased risk of developing colchicine toxicity.
Electrolyte Abnormalities
Major:Gloperba
The colchicine in Gloperba has a major potential interaction with Electrolyte Abnormalities.
Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting. Therapy with colchicine should be administered with caution in patients with electrolyte imbalances. Monitoring serum electrolytes is recommended in these patients.
Hyperkalemia
Moderate:tucatinib
Tucatinib has a moderate potential interaction with Hyperkalemia.
Tucatinib contains 60.6 mg potassium per 300 mg dose. This should be taken into consideration especially in patients with hyperkalemia or impaired kidney function who are on a controlled potassium diet.
Hypokalemia
Major:Gloperba
The colchicine in Gloperba has a major potential interaction with Hypokalemia.
Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting. Therapy with colchicine should be administered with caution in patients with electrolyte imbalances. Monitoring serum electrolytes is recommended in these patients.
Hyponatremia
Major:Gloperba
The colchicine in Gloperba has a major potential interaction with Hyponatremia.
Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting. Therapy with colchicine should be administered with caution in patients with electrolyte imbalances. Monitoring serum electrolytes is recommended in these patients.
Liver Disease
Major:Gloperba
The colchicine in Gloperba has a major potential interaction with Liver Disease.
The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C). Caution is recommended when prescribing colchicine to these patients.
Moderate:Gloperba
The colchicine in Gloperba has a moderate potential interaction with Liver Disease.
Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Caution must be exercised when colchicine therapy is instituted in these patients.
Moderate:tucatinib
Tucatinib has a moderate potential interaction with Liver Disease.
Tucatinib is a hepatotoxic drug. Additionally, its exposure is increased in patients with severe hepatic impairment. This is the reason why the dosage must be reduced in these patients (Child-Pugh C). Consult the manufacturers prescribing information for details on dosage modification.
Renal Dysfunction
Major:Gloperba
The colchicine in Gloperba has a major potential interaction with Renal Dysfunction.
Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Colchicine dosing must be individualized according to the patient's renal function. Caution must be exercised when colchicine therapy is instituted in these patients. Monitoring creatinine function is recommended in patients on long term therapy.
Moderate:Gloperba
The colchicine in Gloperba has a moderate potential interaction with Renal Dysfunction.
Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Caution must be exercised when colchicine therapy is instituted in these patients.
Moderate:tucatinib
Tucatinib has a moderate potential interaction with Renal Dysfunction.
Tucatinib contains 60.6 mg potassium per 300 mg dose. This should be taken into consideration especially in patients with hyperkalemia or impaired kidney function who are on a controlled potassium diet.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.